Rare eye disorder linked to Ozempic-like medications

Medical reports and regulatory bodies have identified a possible link between GLP-1 receptor agonist (GLP-1 RA) medications—including Ozempic, Wegovy, and Mounjaro—and a rare but severe eye condition known as ischemic optic neuropathy. The Australian Therapeutic Goods Administration (TGA) has issued a new warning concerning this specific disorder.

Coverage from Neurology Advisor, The Guardian, The West Australian, ABC News, and Local 3 News emphasizes the formal regulatory response and the emergence of litigation surrounding vision loss claims. These outlets highlight that the risk, while described as rare, has prompted increased public and professional scrutiny of these treatments.

Future developments to watch include potential updates to official safety labels and the progression of ongoing legal actions referenced by Parker Waichman LLP. Coverage does not yet specify how international regulatory agencies outside of Australia will adjust their current guidance.